Erenumab Effectively Reduces Migraine Aura Frequency
- Mar 28
- 1 min read
Research Summary
A recent study published in the Journal of Headache and Pain investigated the effects of erenumab on migraine aura frequency. Erenumab, administered at 140 mg every 4 weeks for 24 weeks, significantly reduced the mean monthly aura days by 5 days compared to baseline in participants with frequent migraine aura (p < 0.001). This improvement partially persisted during a 12-week follow-up, with a reduction of 3 days from baseline (p < 0.001). Greater baseline aura frequency and reduction in migraine days correlated with more substantial aura reduction. These findings highlight the importance of considering aura-specific outcomes in future migraine treatment trials.
Study Details
👥 Research Team: Jakobsen JT et al.
📚 Published In: J Headache Pain
📅 Publication Date: 2026 Mar 26
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.